Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

8 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    HepG2 cells were pretreated with Z-VAD-FMK for 2 hours followed by treatment with IsoA for 16 hours, and the apoptotic cells were evaluated and quantified by Annexin V/7-AAD staining and flow cytometry. The mean±SD of three experiments is shown.***, P < 0.001

    Cancer Res, 2017, 77(4):926-936. Z-VAD-FMK purchased from Selleck.

  • MM.1S cells were incubated with or without pan-caspase inhibitor Z-VAD-FMK for 1 h and then treated with DCZ3301 (4 μM) for 48 h followed by assessment of cell apoptosis using Annexin V/PI staining. Columns (right panel) represent the average percent of Annexin V positive cells from three independent experiments, which are shown as the mean±SD.

    Theranostics, 2017, 7(15):3690-3699. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • Z-VAD-FMK (ZVF) reversed K562 cell apoptosis induced by imatinib (IM) and/or hUC-MSCs-Exo. **P < 0.01 versus K562 + IM group, ##P < 0.01 versus K562 + IM + hUC-MSC-Exo group.

    Cytotherapy, 2018, 20(2):181-188. Z-VAD-FMK purchased from Selleck.

    (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

  • Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

    Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NWfMXG03SXCxcITvd4l{KEG|c3H5 MXS1NO69VQ>? Ml:4NlRp MUDpcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> NHXt[2gzPjF4OUC3OS=>
HGL5 MkHFRZBweHSxc3nzJGF{e2G7 NX73[|VpPTEQvF2= M174[lI1cA>? NVn1[VBGcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? MWWyOlE3QTB5NR?=
HepG2 NUHGNFY6SXCxcITvd4l{KEG|c3H5 NFHObJUzOM7:TR?= M3zmVlFp MWPheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMg NGrVSpgzPjF4NEe5OS=>
BEL-7402 NVvucYJNSXCxcITvd4l{KEG|c3H5 NH3RV4YzOM7:TR?= NVHhTlYyOWh? M1HzWIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> MmHNNlYyPjR5OUW=
CEF NWTXcZJjU2mwYYPlJGF{e2G7 NYHyUnZVOCx|Mzy2O{wyODEQvF2= NIjxUYQyPW2rbh?= MWfkc5dvNXKnZ4XsZZRmeyCSUjDlcpp6dWViYXP0bZZqfHlidH:gOFDwxIViYYSgNVAx|ryP MUSyOlExOjN|OR?=
SP2/0 MVnBdI9xfG:|aYOgRZN{[Xl? M1H2T|ExOM7:TR?= M1SySlFp MlLJSG1UVw>? NHrGWodjdG:la4OgeIhmKGGyb4D0c5NqeyCxZjDTVFIwOCClZXzsdy=> MUmyOlA4PDd|Mh?=
HUVEC-2c NF7wVZVCeG:ydH;zbZMhSXO|YYm= NXOybWlqPTEQvF2= M3fCWFZp M2rZe4Rm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6 NYC5VXpCOjZyMkG3Nlk>
U1 NEj4UYFCeG:ydH;zbZMhSXO|YYm= M2r3U|AuOTByzszN NYTZUZN7Omh? MlHsdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVPSRXhyOjV7OEC5OFI>
ACH-2 Ml3ERZBweHSxc3nzJGF{e2G7 NEHUXVcxNTJyMN88US=> Ml;VNog> M1XDUJJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWeyOVk5ODl2Mh?=
U1 NX7McYs5U2mwYYPlJGF{e2G7 NImyUIcyODEQvF2= M{Ll[lJp M3fpWIlvcGmkaYTzJINie3Cjc3WtNy=> Mn;INlU6QDB7NEK=
A549/V16 MUjBdI9xfG:|aYOgRZN{[Xl? M2nScFUx|ryP NGHLXpcycA>? MVjy[ZBz\XO|ZYOgWGcwXE1vaX7keYNm\CCjcH;weI9{cXN? MUeyOVk1PjB|Mx?=
SGN NWTpSpQ5SXCxcITvd4l{KEG|c3H5 NWnWUYxlOjCvTR?= NHvIbIg1QGh? NXLqemlqcGG|IH7vJIlv\my3ZX7j[UBwdiCDSV[sJINidHCjaX6g[ZhxemW|c3nvckBweiClZXzsJIFxd3C2b4Ppdy=> MVyyOVg4PDZ|Mx?=
HCT116  NYjmWppHSXCxcITvd4l{KEG|c3H5 NIrKUnY2OM7:TR?= NHvMdZIzcA>? NUe4cFNXcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S M3KxUlI2QDZ6OEG4
DTK-SME NXjab4h[SXCxcITvd4l{KEG|c3H5 NVH3T5B5PTEQvF2= M1zrPVJp MVPEUXNQ MXXwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHL1dIl3[WOjaX7l NIL0cFAzPTh2M{i5Oy=>
HL-60 MVzBdI9xfG:|aYOgRZN{[Xl? M2HLPFUx|ryP MYi0PIg> NEDyWYZz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? M4LkWVI2QDJ2MESz
U937 NEDObJVCeG:ydH;zbZMhSXO|YYm= NXHXcVJOPTEQvF2= MXS0PIg> NHjoZYRz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? M2TScVI2QDJ2MESz
A549 M1XVcGFxd3C2b4Ppd{BCe3OjeR?= M4PCU|IxKM7:TR?= MV:yOIg> MUHy[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JGhHS1BidILlZZRu\W62 MVWyOVc6PDF2OR?=
HeLa NFrJenBCeG:ydH;zbZMhSXO|YYm= NY\G[4wzOTEQvF2= Mn25OFhp MWnk[YNtcW6nczD0bIUhemG2ZTDv[kBieG:ydH;zbZMh\HKjbXH0bYNidGy7 MlPiNlU4PzJ3NEW=
SGC-7901 M3y3eGFxd3C2b4Ppd{BCe3OjeR?= MWqyNOKh|ryP MWqxbC=> MYTpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;4ZYxqeGyjdHnu NGrE[lIzPTd4N{C3Oi=>
MCF-7 NEPHfolCeG:ydH;zbZMhSXO|YYm= MV[xNO69VQ>? MXSybC=> NFHOd2lqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND MVGyOVczOjFzNB?=
A549 Mn7aRZBweHSxc3nzJGF{e2G7 MXGxNEDPxE1? M1\ySlI1cA>? M2fJOWROW09? NFKzWY5xem:vb4Tld{BJSkNvdILlZZRm\CCDNUS5JINmdGxic4Xyeol3[WxiJjDheJRmdnWjdHXzJJRp\SClbHXheoVlKFCDUmCg[ZhxemW|c3nvci=> M2XRe|I2Pjh|NU[4
U87 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZOVDPxE1? NGX2ZnMycA>? M4\CbZJm[2:4ZYLzJINmdGxiZ4Lve5RpKG[{b32gWG1bKHS{ZXH0cYVvfA>? MVOyOVY5OTZ4OB?=
Neocortical Neuron NETNW5FP\XW{b4TvfIlkcXS7IFHzd4F6 M1XJfFExOM7:TR?= NYXPemh1OWh? MoDBZY51[Wexbnn6[ZMhUG:rYX3p[IUhSS2LbnT1Z4VlKE6ndYLveI95cWOrdIm= MXWyOVY4PTByMR?=
Primary human placental cytotrophoblasts M1r5U2Fxd3C2b4Ppd{BCe3OjeR?= M4HpXVMx|ryP NXOwT3o6OjSq MkXtSG1UVw>? NH\zXJJz\X[ncoPld{B1cGViaX7obYJqfGmxbjDv[kAyOc7{LVjTSFIh[nlidILpZ4xwe2GwwrC= NGm4bnUzPTZ2MkW5Ni=>
MM NUTQNVZJSXCxcITvd4l{KEG|c3H5 MnXYOVDPxE1? MVOyNI1qdg>? MWLwZZJ1dHliaX7obYJqfHNiU1jLMYlv\HWlZXSgJINmdGxiZHXheIg> NEDXOJIzPTV|MEC5PC=>
DLD1 MWfBdI9xfG:|aYOgRZN{[Xl? M1XjRVIxyqEQvF2= NVXkXJNROWh? MljJdIFzfGy7IILleoVze2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCZU2Cx NYTTOWRiOjV3MkSyOFY>
MDA-MB-231 MljGR5l1d3SxeHnjbZR6KEG|c3H5 MXGxNO69VQ>? MmK5NYg> NXL4bIds[XWpbXXueJMh[2WubDDk[YF1cCCjZoTldkBEUFWDIITy[YF1dWWwdB?= MX6yOVUzOTVyMR?=
MKN28 MYTBdI9xfG:|aYOgRZN{[Xl? MmDwNVDPxE1? MnrxN|BucW5? MoLsSG1UVw>? MmXKbY5pcWKrdIOgWG5HNc7zIIDseZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| M4HP[|I2PTF|OU[w
HL-60 M3G2TWN6fG:2b4jpZ4l1gSCDc4PhfS=> Ml6yNVAx|ryP MWKxbC=> MULEUXNQ M3XYZ:KhcW2ycn;2[ZMhfmmjYnnsbZR6KG:oIGTDUmF{NXS{ZXH0[YQh[2WubIO= NIDvUoEzPTVyMkmzNi=>
AGS MVvBdI9xfG:|aYOgRZN{[Xl? M2PJT|Ex|ryP MUWxbC=> NHL3S2NxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= MX:yOVQ6OjJzNB?=
A549  M3\hfmFxd3C2b4Ppd{BCe3OjeR?= NGi4WokyOM7:TR?= MkDnNlRp MVjicI9kc3NiRF3BV{1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCjbnSgZZBweHSxdHnjJINmdGxiZHXheIg> NVXs[WZNOjV2M{S5PFk>
INS-1 NWrWTYR7SXCxcITvd4l{KEG|c3H5 MXG1NO69VQ>? NGW5N5Y3cA>? NYHNZ2Z3TE2VTx?= M2TnVIRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBm[XKueTDhdI9xfG:2aXOgZ4VtdHQEoB?= NWHTR2lpOjV2M{C4PVc>
Primary hepatocytes  MW\BdI9xfG:|aYOgRZN{[Xl? MXu1NO69VQ>? M1fYOVE5cA>? MnvZbY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?= MnLlNlU1ODd3M{i=
L929-A  M1:4WmN6fG:2b4jpZ4l1gSCDc4PhfS=> NIO4PVczOMLizszN NGTxc4wzPGh? NEjmb4NqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHi= MofpNlU{QTh3NEC=
L929-N M12zRWN6fG:2b4jpZ4l1gSCDc4PhfS=> NEDWdXczOMLizszN NWjPbYRqOjSq MlTk[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u NWTVSVlxOjV|OUi1OFA>
Cytotoxicity Assay NXfLTVJ5S2WubDDWbYFjcWyrdImgRZN{[Xl? MUWyNO69VQ>? NYHU[lZuPDiq M3K3TpBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh? NI[2WIczPTN7MkGxOi=>
COS7 M3fkU2tqdmG|ZTDBd5NigQ>? M3XLd|Ex|ryP M4DuVFI1cA>? MVjpcoNz\WG|ZYOgZ4F{eGG|ZTCzM|ch[WO2aY\peIlmew>? MV6yOVM5PDB{NR?=
COS7 MYLBdI9xfG:|aYOgRZN{[Xl? NGTW[5YyOM7:TR?= M2XaZ|Q5cA>? MWfwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NEC3NHIzPTN6NECyOS=>
A375 NVzMNXBpSXCxcITvd4l{KEG|c3H5 MnPGN|DPxE1? NHS2U2wzcA>? NE\TZVlxemW4ZX70d{B1cGViZIL1[{1qdmS3Y3XkJHBCWlBiY3zlZZZi\2V? M1vx[FI2Ozd4MUG1
A549 NVnYU5g6SXCxcITvd4l{KEG|c3H5 Ml;5OVDPxE1? MX[yOIg> NE[2VWFz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFv MnnnNlU{PDl5OEG=
A549 MVnBdI9xfG:|aYOgRZN{[Xl? NHuyS3UzNjVvMkZOwG0> Mlr2NYg> M1zEdIRm[3KnYYPld{B1cGVicH;weYxifGmxbjDv[kBieG:ydH;0bYMh[2WubIOg[IVx\W6mIH;uJINwdmOnboTyZZRqd26| NIjTZoozPTN2MkSyOy=>
 NBL-W-S  MV7BdI9xfG:|aYOgRZN{[Xl? MnjnOVDPxE1? MWGxbC=> NHq1e4xnfWyueTDy[ZNkfWW|IHPlcIwhfmmjYnnsbZR6KGGodHXyJGdCVlRvNkGgeJJm[XSvZX70 M1WxSVI2OzJ|MkKy
Caki-1  MWDBdI9xfG:|aYOgRZN{[Xl? NFrKRng1OM7:TR?= NGnXTFA1QGh? M2HlNJJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM> NEm3PIQzPTJ5OUG5NS=>
769-P M2rNZmFxd3C2b4Ppd{BCe3OjeR?= NHvudYo1OM7:TR?= MkDKOFhp NEjqTpFz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{ MUOyOVI4QTF7MR?=
H9c2 NXG5fIhKSXCxcITvd4l{KEG|c3H5 M2HHZVUx|ryP MYexbC=> MYTpcohq[mm2czDEU3gucW6mdXPl[EBk[XOyYYPlJFMh[WO2aY\heIlwdiCkdYSgco91KHSqZTDsc5N{KG:oIHPlcIx{ M3zpdFI2Ojh|OEG5
K562 NELLUJlCeG:ydH;zbZMhSXO|YYm= NUe5SGE5PTEQvF2= NWrLVo5IPGh? NF\hc45qdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ MVKyOVI1OTZzOR?=
L929 MlrDRZBweHSxc3nzJGF{e2G7 M2DibFEx|ryP MYS2bC=> NEe3bVdqdmS3Y3XzJI5m[3KxcITvd4l{KHerdHigWG5H MYSyOVE6PTZ4MB?=
A549 NW\YSFdmSXCxcITvd4l{KEG|c3H5 MVuxNO69VQ>? M4DxUlNp MXTy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= NGn5Z4MzPTF4MU[5PS=>
MCF-7 Mn;6RZBweHSxc3nzJGF{e2G7 NIfrW20zOM7:TR?= NGjve3UzcA>? NVLV[JRS\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>? NHPUeWIzPTF6MkK0NC=>
OS NUPnRYdVSXCxcITvd4l{KEG|c3H5 MnPCNlAwPDEQvF2= MWK3Nog> M3HwbYlvcGmkaYTzJG9UKGOnbHygeoli[mmuaYT5JJJm\HWldHnvckBjgSCFNjDj[ZJidWmmZR?= NH\HfnYzPTF3MkO5PS=>
HUVECs NWD6blVDSXCxcITvd4l{KEG|c3H5 NIXBVmUyOM7:TR?= MYKybC=> MVxCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MlnONlUyOzh5MEO=
EA.hy926 NXHGT3RlSXCxcITvd4l{KEG|c3H5 NWHSUZBVOTEQvF2= MYqybC=> NILYN2bDqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEWDLnj5PVI3 Mon3NlUyOzh5MEO=
Ebs MX3BdI9xfG:|aYOgRZN{[Xl? MkLrNVAuOTByzszN NWP3cXA2OjSq MmWxxsBOVVSVIHflcoVz[XSrb36gdoF1\SCmZXPy[YF{\WRiYYOgeIhmKGOxbnPlcpRz[XSrb36gc4Yhgi2YQVSu[o1sKGmwY4LlZZNm\A>? NGHiVIUzPTF|NEixOy=>
Jurkat NGnaeWNCeG:ydH;zbZMhSXO|YYm= NUCwd5cxOjEQvF2= MWOyOIg> MkjYSG1UVw>? M13KfZBienSrYXzsfUBqdmirYnn0JINmdGxiZHXheIghd2ZiSoXyb4F1KGOnbHzzJIlv\HWlZXSgZpkhOTByNUitSlQh[2:vYnnu[YQhf2m2aDDWVGHDqA>? NGWwZZEzPTF{MEeyNy=>
K562 MVTBdI9xfG:|aYOgRZN{[Xl? NXXzd5Q6OC5zLUJOwG0> NYXyeYRZOWh? MknJbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWmyOVEyQTF6OB?=
IMR-32 M4W0UWFxd3C2b4Ppd{BCe3OjeR?= M1frU|QxyqEQvF5CpC=> MUSybC=> NGDMT3Rl\WO{ZXHz[UBqdiCjcH;weI91cWNiY3XscJMh[2:vcHHy[YQhfG9iVD2yJJRwgGmw NEnX[FkzPTB6NEe1OS=>
RPMI 8226 M2\Sb2Fxd3C2b4Ppd{BCe3OjeR?= MUOxNFDPxE1? MXuxbC=> M37ZR4FtdW:|dDDjc41xdGW2ZXz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z NFzBXlEzPTB|N{i1NS=>
U266  NIDkbmVCeG:ydH;zbZMhSXO|YYm= NIXEUlgyODEQvF2= NXnofVhEOWh? NHO0ZpRx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= MUmyOVA{Pzh3MR?=
H929  MVfBdI9xfG:|aYOgRZN{[Xl? MWKxNFDPxE1? NX\4SmtCOWh? NGj6eG1x[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= NHPnZ3AzPTB|N{i1NS=>
MM.1S  MoC0RZBweHSxc3nzJGF{e2G7 NGn0ZlUyODEQvF2= M1\WOVFp NEjERYRm\m[rY3nlcpRtgSCycnX2[Y51eyC|b4Lh[oVvcWJvaX7keYNm\CClZXzsJIRm[XSqIHPvcYJqdmVid3n0bEBv\WO{b4P0ZZRqdi1z NFfnOlYzPTB|N{i1NS=>
C6 NH7XdYpCeG:ydH;zbZMhSXO|YYm= MnHVOVDPxE1? NHuwTVc1QGh? MVjwdoV3\W62czD0bIUhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDjZZV{\WRiYomgdJJm\26nbn;sc45m NGjoWnUzPTBzM{S3PS=>
AGS NFjNO4NCeG:ydH;zbZMhSXO|YYm= NGT5bGs2OM7:TR?= M{LoO|I1cA>? NIPJdHdi[m:uaYPod{DPui2uYYDhZ4hwdmVvaX7keYNm\CClZXzsJIRm[XSqIHHu[EBqdmirYnn0[YQh\3Kxd4To MlHkNlUxODl4OUi=
HeLa  NYXYOmZXSXCxcITvd4l{KEG|c3H5 NHHIepc1OM7:TR?= NYfzPFZxOjSq M3\mVYlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiYYDvdJRwe2m|IHnu[JVk\WRiYomgd4lTVkZzMkG= M2XGWlI1QTJ6Nki1
THP-1  NHPoWFRCeG:ydH;zbZMhSXO|YYm= MYexNO69VQ>? M17BdFFp NYnGUnc{emWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCDTFGtV2RVyqB? MmHzNlQ6OjN4NUO=
P815  M4PUcWFxd3C2b4Ppd{BCe3OjeR?= NVi1fI97OTByINM1US=> Mnm0NVJp NWL3ZplZTE2VTx?= MVvpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NXftTHZzOjR7MkOyO|M>
HCT116 NVzTfndVSXCxcITvd4l{KEG|c3H5 NIXIfZAzOM7:TR?= NH7ONmMzPGh? MmO5ZYJzd2ejdHXzJI9nKFSTLXnu[JVk\WRiYYDvdJRwe2l? NXjPXGtTOjR6OUC0OFk>
SW1116  MkGyRZBweHSxc3nzJGF{e2G7 NVTmfYhROTBiwsXN MXWxbC=> NXH0R404TE2VTx?= NVKzZW1wemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NVTrTpJpOjR6N{SyPFY>
LOVO MWfBdI9xfG:|aYOgRZN{[Xl? MnrHNVAhyrWP M1zoOVFp MYXEUXNQ NFnydXVz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l M1vaS|I1QDd2Mki2
SNU449  NVTYTYU{SXCxcITvd4l{KEG|c3H5 M1HOTFIx|ryP NXXWWYR4PDiq M1jJXGROW09? Mm\R[IVkemWjc3XzJI1qWi12NUGtbY5lfWOnZDDhdI9xfG:2aXO= MXyyOFg1OTZ|OB?=
Caco-2 MVLBdI9xfG:|aYOgRZN{[Xl? NH:zR5g1OOLCid88US=> NF;DOJU1cA>? NHv4eWNxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? NIW2OJczPDh{MkG4Ny=>
macrophage MnHER4VtdCCYaXHibYxqfHliQYPzZZk> M3jtXlAuOjByzszN NX\JZpkzOjSq Mn;jbY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm MknuNlQ4QTl3NkW=
AGS  M2jOUmFxd3C2b4Ppd{BCe3OjeR?= NE\zSpMzOM7:TR?= MWCxNog> MlTFSG1UVw>? MYTy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJJJme3CxboPlJJRwKHSqZTDFeG9C[yCocnHjeIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2\KUVI1Pzh7N{Cz
LCC9  MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MknqNVAx|ryP M3XBb|Vl M1S5fYJtd2OtczDj[YxtKGSnYYToJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25iTEG3JIFv\CClaHzvdo9yfWmwZR?= MYWyOFc5PTJ3Nh?=
U937  NFjQVpBv\WO{b4D0c5NqeyCDc4PhfS=> NF;hZo0yOMLizszN M2jiNVMxyqCvaX6= M{TDV4lv\HWlZYOgcoVkem:ydH;zbZMh[2:vYnnu[UB4cXSqIGTOSi=> MWqyOFc4Ozd3Nh?=
T cell NHnicVhE\WyuIIDyc4xq\mW{YYTpc44h[XO|YYm= NYi4[3FbOC1zMEFOwG0> NEK4R5U4Omh? M3WwemlEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO| MonFNlQ4Pjh5MEe=
HeLa  NX7UPHN2SXCxcITvd4l{KEG|c3H5 NV\GdZRyPTEQvF2= NFHsSIw4Omh? NVXkc3dKTE2VTx?= NHfUbolxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClb33wc5Vv\HQEoEJihLM2 MWGyOFc2PDd6Nh?=
HeLa  MlGxRZBweHSxc3nzJGF{e2G7 M2LjSVExOM7:TR?= M3z4SFI1cA>? M{DI[JN2eHC{ZYPz[ZMhemG2ZTDv[kBk\WyuIHTlZZRpKGmwZIXj[YQh[nlib4\ldoV5eHKnc4Ppc44hd2ZiR{W5V{BweiCJN{HSJJAyPTCpbIXl[OKh M13wOlI1PzJ{NE[4
IEC-6  M4K0OWFxd3C2b4Ppd{BCe3OjeR?= MUKxNO69VQ>? MYWyOIg> NU\ad5JbeHKndnXueJMhXGOmQT3pcoR2[2WmIHPhd5Bie2VvMzDjcIVifmGpZTDhcoQh|rJvY3H0[Y5qdiCmZXfyZYRifGmxbh?= M{[ycFI1PzFzNUex
HCT116 NUfWZVc{SXCxcITvd4l{KEG|c3H5 NWnRWphnOjEQvF2= M1LzNVI1cA>? NXO4UI54cW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2 MlTRNlQ4OTN6MUK=
L02 Mo\uRZBweHSxc3nzJGF{e2G7 M2T4PVIx|ryP Ml;JNYg> Mm\xdJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?= M4nUO|I1PzB4NE[x
A375 NUHxW3JkSXCxcITvd4l{KEG|c3H5 NEXSXHYzOM7:TR?= NYHFWGpuOjSq NFPVO4Nz\X[ncoPld{BlcWOrdILpco9v\SCELXnu[JVk\WRiYYDvdJRwe2m| NFPVRlYzPDZ7OUGxNS=>
HDPC Ml;xRZBweHSxc3nzJGF{e2G7 M2n1TFUxyrWP M3vPdFI1cA>? NHXvOXdqdmirYnn0d{BPVy2rbnT1Z4VlKGGyb4D0c5Nqew>? M1y5dVI1PjN2NUmz
A549 NVzWUJhoSXCxcITvd4l{KEG|c3H5 NEC5SJo2OML3TR?= MoTENog> MnnMSG1UVw>? NGCydldxemW4ZX70d{B1cGViaInwc4RqeGyxaXSgSG5CKGOxboTlcpQheGijc3WgbY5lfWOnZDDifUBk\XCqYXzvZ4hzd22rbh?= NUKyZWRCOjR3OEixN|U>
 BV-2 NX3Hc4FvSXCxcITvd4l{KEG|c3H5 M3XadFIx|ryP NY\lUpgzOmh? MUTzeZBxemW|c3XzJHVXNWmwZIXj[YQh[2i{b33heIlvKGW6dIL1d4lwdiCjbnSg[Ilt[XSrb36gc4YhfGinIH71Z4xm[XJiZX72[YxweGV? NWrMfFNPOjR3NUixNVg>
HT-29  NV3qc|lFSXCxcITvd4l{KEG|c3H5 NXH0[o1LPTEQvF2= NWXIZnU5PDiq M{TWOIJtd2OtczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nlia3HlcZBn\XKxbB?= M3OydFI1PTR7MUe1
A549 NHzMZoVCeG:ydH;zbZMhSXO|YYm= NUDIcVhqPc7:TR?= NWr2eGpQOjSq MkfSd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= NGHrNVUzPDV{OUi3NS=>
MIA-PaCa-2 NUO0NHhWSXCxcITvd4l{KEG|c3H5 NWPLUYU4OjSq MlnxZoxw[2u|IHPs[YF3[WenIH;mJINie3Cjc3WtN{BqdmS3Y3XkJIJ6KGKxdHigRU01PDN4NUSgZY5lKHCjY3zpeIF5\Wx? M3nvXVI1PTFyOUmy
Caki-1 NGPOU|BCeG:ydH;zbZMhSXO|YYm= MmjmNlDPxE1? M{frTFFp MkLrbY5pcWKrdIOgV2NRNWmwZIXj[YQh[XCxcITvd4l{ MlLMNlQ2ODR4OEG=
CLL M{XTSmFxd3C2b4Ppd{BCe3OjeR?= NUH6RWlJOjYQvF2= MUWxbC=> NWi2[|JoeGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? Mn;pNlQ1Pjd4M{S=
SGC-7901 Ml;iRZBweHSxc3nzJGF{e2G7 MojrNVDPxE1? NVv5NpY1OjSq NUDpepdXeHKxbX;0[ZMhfGinIFPHTWkucW6qaXLpeIVlKGOnbHyg[5Jwf3SqIHnuJHNISy15OUCxJINmdGy| MUSyOFQ2PDR6OB?=
k1735 MUTBdI9xfG:|aYOgRZN{[Xl? Mle4NlDjiIoQvH2= MlrXOIg> NVfF[otpcW6qaXLpeJPDqFOjbH3vcoVtdGFvaX7keYNm\CCjcH;weI9{cXN? MVqyOFQ2OTFzNh?=
HaCaT  MUTBdI9xfG:|aYOgRZN{[Xl? MmrsNVAx|ryP NGDaT3YycA>? NGO2VphjdHWwdIOgWXZDNWmwZIXj[YQh[XCxcITvd4l{KGmwIFjhR4FVKGOnbHzz NGK4dGczPDN3Nkm5Oy=>
podocytes NFLLb4JCeG:ydH;zbZMhSXO|YYm= M37GflIxOM7:TR?= M3rwRlZp NEX5d3RqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdG Mmm1NlQ{Ozd5N{e=
 KB M{HYXmFxd3C2b4Ppd{BCe3OjeR?= NGLtTGE2OM7:TR?= MVqyOIg> Mn\obY5pcWKrdIOgUIlkdy2DLXnu[JVk\WRiY3HzdIF{\S1|IHHu[EBRSVKSIHHjeIl3[XSrb36= M1TM[FI1OzN5NEmy
 HepG2  MUnBdI9xfG:|aYOgRZN{[Xl? MlO3NVDPxE1? M2XZNFI1cA>? M3\SPZJm\HWlZYOgeolu\W62aX6gZ4xm[X[jZ3WgZ4F2e2WmIHL5JGxRWw>? NIDxOpMzPDN{NUixOi=>
fetal rat lung fibroblasts  M3;MSGtqdmG|ZTDBd5NigQ>? MnzLPFDPxE4EoB?= NEfa[JIycA>? MmnNbY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> MWCyOFMyPDF|NR?=
PDL fibroblasts MkX3T4lv[XOnIFHzd4F6 NELZTJM5OM7:TdMg NUjjUmNOOWh? M2[zXYlvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh M3LQXFI1OzF2MUO1
MB49 M1\jPGFxd3C2b4Ppd{BCe3OjeR?= NVLXVW9sOjEQvF2= MXixbC=> NIHpSohz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? MofrNlQzQDJ2M{O=
5637 NYjE[oVXSXCxcITvd4l{KEG|c3H5 MXWyNO69VQ>? NYrWUWFxOWh? NFruZ2Jz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? NUPK[INIOjR{OEK0N|M>
A549  NGLZenVCeG:ydH;zbZMhSXO|YYm= M{nCd|ExOM7:TR?= M2PCR|Q5cA>? NXS5XmF1e3WycILld5NmeyC2aHWgZZBweHSxc3nzJINifXOnZDDifUBxcXCncnnu[eKh M36zd|I1Ojd{MkCx
MCC-2 MWPBdI9xfG:|aYOgRZN{[Xl? M1HaRlIxKM7:TR?= MY[2bC=> M2\z[mROW09? M{XKVoJtd2OtczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmViYYDvdJRwe2m|IHPlcIwh\GWjdHi= NHm2Z|IzPDJ4Mk[1PC=>
ADF M{XDbGFxd3C2b4Ppd{BCe3OjeR?= M4PIT|Qx|ryP MWe2bC=> NHLN[Y5qdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NELCS5ozPDJ{OEKzNi=>
 U373  MkPURZBweHSxc3nzJGF{e2G7 NYLTTHFrPDEQvF2= MmPHOog> NUPseFVYcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> MmfHNlQzOjh{M{K=
RKO-HIPK2i M1m2PWFxd3C2b4Ppd{BCe3OjeR?= NVzIUHRsPDEQvF2= MXy2bC=> NWG1OVRTcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI> MV6yOFIzQDJ|Mh?=
HEC-1B NGDNUHdCeG:ydH;zbZMhSXO|YYm= MXmyNO69VQ>? Ml22NYg> NEDodGFz\WS3Y3XzJHRRNWmwZIXj[YQh[XCxcITvd4l{yqClYYPwZZNmNTNiYX7kJINie3Cjc3WtPS=> M1\aeFI1OjF|M{W4
4T1 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkexNk42NTFyzszN Mn3XOIg> MVfEUXNQ NFj2VHVz\XOldXXzJJRp\SCleYTveI95cWOrdImgc4YhPFRzIHPlcIx{KGmwZIXj[YQh[nliU2DEWEBqdiCjIHPvcoNmdnS{YYTpc44h\GWyZX7k[Y51KG2jbn7ldi=> NHvneXIzPDJyNkG2NS=>
OS  MVPBdI9xfG:|aYOgRZN{[Xl? NFu2d4wzOM7:TR?= M3HnelRp MUjpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliUFTU Mn7HNlQzODR7M{e=
RPE M3jQ[GFxd3C2b4Ppd{BCe3OjeR?= NGi5fXAyODEQvF2= M{\4TlQ5cA>? Ml:ydIFzfGmjbHz5JIlvcGmkaYTzJJRp\SClYXzwZYlvNTFiYX7kJE0zKGGldHn2ZZRqd25iYYOge4VtdCCjczD0bIUh[2G|cHHz[UBi[3SrdnH0bY9v MVqyOFIxOjB3Mh?=
UD29a NX7GSnE4SXCxcITvd4l{KEG|c3H5 NGnQTFA2OM7:TR?= M4nhcVI1cA>? NEnWTI1qdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgUnVVOw>? Ml;iNlQyQTB3N{S=
SH-SY5Y  NGnxdpNCeG:ydH;zbZMhSXO|YYm= MWOxNO69VQ>? M3XKflI1cA>? MUjheJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe= NHrKfpgzPDF2NUS2Ny=>
HeLa  MkjXRZBweHSxc3nzJGF{e2G7 MlnYNVAwOjEQvF2= M3nQdVI1cA>? NGDpOFlqdmirYnn0d{B1cGViYXP0bZZqfHlib3[geIhmKG2jan;ybZR6KG:oIITo[UBu\W2kZYLzJI9nKHSqZTDjZZNx[XOnLX\hcYltgQ>? NGD2dHEzPDF|N{K2Oi=>
SCCVII  NX3VeXB7SXCxcITvd4l{KEG|c3H5 NIj3NnYzPc7:TR?= NW\pdIJJOWh? NELPXIZqdmirYnn0d{B1cGViY3XscEBscWyuaX7nJIFnfGW{IHThd4F1cW6rYh?= NXzsfJlWOjRzMk[0OlQ>
RAW 264.7 M17WSmFxd3C2b4Ppd{BCe3OjeR?= NFjHW|gzOM7:TR?= M37ndVE5cA>? M4fnSolv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl? MWSyOFEyPjdyNx?=
A549  M4iyUmFxd3C2b4Ppd{BCe3OjeR?= NUTvelhoOi53zszN NHPIN4MzPGh? NYXhXm44\GWlcnXhd4V{KG:{aXTvcolvNWmwZIXj[YQh[XW2b4DoZYd6KGG|IIflcIwh[W6mIFzvd5Mhd2ZizqVPjI0h[Wy|bzDvZ4N2enKnZDDkeZJqdmdiYYX0c5Bp[WerYzDwdo9k\XO| MnniNlQyODJ3MkK=
UM-SCC-10A  NWXtfYNjSXCxcITvd4l{KEG|c3H5 NUS3SIs{PTEEtV2= M{DzNlJp NUj6[JZJemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCqaXfoMYRwe2ViaYPvZYxidnSxbHHjeI9v\Q>? MofBNlQxQTh5NUO=
BGC-823 NGTtd5ZCeG:ydH;zbZMhSXO|YYm= NV\v[IpkOTBizszN NHjCU24zPGh? M1Tx[ZJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? M3f1WVI1ODl6NUGx
Nalm-6  NHLtWGJCeG:ydH;zbZMhSXO|YYm= MYqyNO69VQ>? MX:0bC=> M{nLTYlvcGmkaYTzJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|IHHjeIl3[XSrb36gZY5lKFCDUmCtNUBkdGWjdnHn[S=> NHvKRXMzPDB|OUm2Oy=>
KHOS  NX;M[3lLSXCxcITvd4l{KEG|c3H5 MUC0NO69VQ>? NF3DSlUzPGh? NUXxXZI{[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> M4jLXFI1ODJ3M{[x
G292 MULBdI9xfG:|aYOgRZN{[Xl? NGPxcZc1OM7:TR?= MlPDNlRp NV[0Vpdn[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> NWO1NmRsOjRyMkWzOlE>
MG-63 Ml\kRZBweHSxc3nzJGF{e2G7 MnW4OFDPxE1? MWiyOIg> Mo\MZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= MWSyOFAzPTN4MR?=
EBV-transformed B cells NFLoZoZCeG:ydH;zbZMhSXO|YYm= NGrLVVAzOM7:TR?= MnHENog> MU\EUXNQ NIe1WIJjdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? MW[yOFAxQDZ{OB?=
IM-9 B NHK5[FNCeG:ydH;zbZMhSXO|YYm= MofMNlDPxE1? NX35XHBXOmh? NWDsTYJvTE2VTx?= Mnj2Zoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ NHXlc4szPDByOE[yPC=>
CNE1 M4S3[mFxd3C2b4Ppd{BCe3OjeR?= NXuyR2ZbOjEQvF2= MoHROFhp NYrLepBx[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MVGyN|k5PTB{OR?=
CNE2 MlGwRZBweHSxc3nzJGF{e2G7 MUiyNO69VQ>? M3HmS|Q5cA>? Mmm2Zoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> M3nxO|I{QTh3MEK5
HL-60 MV3BdI9xfG:|aYOgRZN{[Xl? NEXLbYQ2OML3TR?= M4jqZVFp M3\mXGROW09? NVfUdGRwcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQlGxOFU> NH\xcGQzOzl2OEe1NS=>
L929 MUnBdI9xfG:|aYOgRZN{[Xl? NG\6ZVUyNjJ34pETOeKh|ryPwrC= Mon6NlRp MVXheYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> NGnmbFIzOzl2MUe2PS=>
Jurkat NHf0dmNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnrrNu69VQ>? MXO0bC=> NYHvUZI2emW4ZYLz[ZMh\3Kxd4ToJIlvcGmkaYTpc44h[W6mIN8yMYNifGWwaX6g[IVkemWjc3WgZpkhUFNvQWPB M2HrXlI{QDl4ME[x
RAW264.7  M3n1eGFxd3C2b4Ppd{BCe3OjeR?= M4i5WlExKM7:TR?= MkL3NlRp MXnk[YNz\WG|ZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFfB NFe1XHMzOzh{MEKwNy=>
A431  NHjGU5FMcW6jc3WgRZN{[Xl? NFzwboI1OM7:TR?= MVuybC=> MmPrZoxw[2u|IH\pd4V1cW5vaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnczDhcoQhWEGUUB?= NIn4dpIzOzhyMEC1PC=>
Jurkat M{jhNGNmdGxiVnnhZoltcXS7IFHzd4F6 NETP[IkzPS1zMEFOwG0> NF3NeVc3cA>? NEPZRoxqdmirYnn0d{B7NU[DLVPNT{1qdmS3Y3XkJINmdGxiZHXheIg> Mki5NlM6OzN3M{K=
COS-7  NIG5SVFHfW6ldHnvckBCe3OjeR?= NHLncpc2OML3TR?= NWPVcVZDOjSq MVTh[oZm[3S|IITo[UBxem:lZYPzbY5oKG:oIFHUUlF{KHerdHigdI9tgVFidILhZ5R{ M{LyRVI{QTN|MkC4
CAL27 MkLMRZBweHSxc3nzJGF{e2G7 MXexNEDPxE1? M3jUb|Jp MkjKd5VxeHKnc4Pld{BEfXJvTmDzMZJm\HWlZXSgeoli[mmuaYT5JIJ6KHWyIITvJFkxLQ>? MUCyN|kyPzN7Nh?=
THP-1  NVLCeng5SXCxcITvd4l{KEG|c3H5 NEnvO2UyOC13MN88US=> Mn[5Nog> MXXpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1emmydH;sbYRm NHfTNW8zOzlyMEK5PS=>
K562 MnuzRZBweHSxc3nzJGF{e2G7 M1LkSlIx|ryP M1yzXlQ5cA>? MWPpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA1NU2X MmnQNlM5PzZ6Mk[=
HL-60 M{L3cmFxd3C2b4Ppd{BCe3OjeR?= MU[xNFDPxE1? NVvKcYRROjSq M2e2dYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGGkaXX0ZY5mKGSrdHXydIVv\XQEoB?= NVnRbYJ4OjN6NkW3O|g>
HeLa  MUjBdI9xfG:|aYOgRZN{[Xl? NIOzeW8zOM7:TR?= MUeybC=> NHj5bHJqdmirYnn0d{BFVU2SIHnu[JVk\WRiYYDvdJRwe2m| NUK5[o5rOjN6NkO5OlY>
U251 MnXDRZBweHSxc3nzJGF{e2G7 M3HBPVIx|ryP NUH5NIpnOjSq M3XybolvcGmkaYTzJINie3SrY3nuJIlv\HWlZXSgS|IwVSCyaHHz[UBienKnc4SgZY5lKGGyb4D0c5Nqew>? M4flSVI{QDF4OEG2
HL-60 M{LjUmFxd3C2b4Ppd{BCe3OjeR?= Mo\jOVDDvU1? MlXvOIg> MYficI9kc3NidHjlJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUmsJIFv\CCSQWLQJIlv\HWlZXSgZpkhPnN? M{Lo[|I{QDB2N{C2
Ec-109 M4PqO2Fxd3C2b4Ppd{BCe3OjeR?= MVOxNEDPxE1? NUj5R3lWPDiq NF\aVlBz\XC{ZYPz[ZMhWEVvbXXkbYF1\WRiRXOtNVA6KGOnbHygZZBweHSxc3nz NHn1U|AzOzd6Mk[0NS=>
RKO NHL2RYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWexNEDPxE1? MUSyOIg> NEL6dXJqdmirYnn0d{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliY3H1d4VlKGK7IFTBRi=> M4DmZlI{PzV6ME[0
T98G NEPTOYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWLrNnJpOS1zMEFOwG0> MVGyOIg> NXyyW2tOcW2ycn;2[ZMh[2WubDD2bYFjcWyrdImgZ491emWjdH3lcpQhf2m2aDDUVy=> NGLSWlIzOzd4OUK3OS=>
Jurkat MlrxR4VtdCCYaXHibYxqfHliQYPzZZk> NGDTd|AyODBvMkCw{txO M{XneFI1cA>? NYe5d3dncW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMg NIrNfWwzOzd|MkS4NS=>
Molt-3  MYnBdI9xfG:|aYOgRZN{[Xl? MXm1NO69VQ>? NUKz[YpTOmh? M3;TXJJm\HWlZYOgcYVt[XSxbnnuMYlv\HWlZXSgZZBweHSxc3nz NV;GT4dxOjN5MkWwNVM>
hMSC12 NFzUWFNCeG:ydH;zbZMhSXO|YYm= Ml3oNVAx|ryP MWK0[C=> M{\OfIlvcGmkaYTzJI9{fGWxZ3XubYMh[3WudIXy[U1qdmS3Y3XkJINmdGxiZHXheIgh[W6mIHPhcINq\mmlYYTpc44> MYKyN|Y2Pzh{Mh?=
HM7  NEDvc21CeG:ydH;zbZMhSXO|YYm= M1rMOFIx|ryPwrC= M4LVeVFp Mn\yZoxw[2u|IHHwbYN2dGG{ZX6gRUBi[2W2YYTlMYlv\HWlZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIGDBVnAh[2ynYY\h[4U> MVqyN|U5OzRzMh?=
Hep-2  M3H5TGFxd3C2b4Ppd{BCe3OjeR?= NFjCWJIzOM7:TdMg NHzDXIMzPGh? M3vYfWROW09? MV7hcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?= NGTo[GUzOzV6MECzNi=>
HSCs M3K4UmFxd3C2b4Ppd{BCe3OjeR?= MVq1NO69VQ>? M4HGSlI1cA>? NIXObJNFVVOR NYnoOJp{cW6qaXLpeJMhdmmub4TpcoljNWmwZIXj[YQhTE6DIHThcYFo\SCrbnTpZ4F1\WRiYomgVGFTWCClbHXheoFo\Q>? NUnGeoNvOjN2OUm4O|Q>
HL-60  M4HQTmN6fG:2b4jpZ4l1gSCDc4PhfS=> NVr4eGZbOjEQvF5CpC=> MXKyOIg> MVXy[YR2[2W|IITo[UBkgXSxdH;4bYMh\W[oZXP0JI9nKEW{eUW= NFXPVFAzOzR7NES4NC=>
HA MkfTRZBweHSxc3nzJGF{e2G7 MmrBOVDPxE1? MXOyOIg> M2fiTpN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? MmOyNlM1PzV7NU[=
C666-1 MoSxRZBweHSxc3nzJGF{e2G7 M{i2ZlUx|ryP M2DiPFI1cA>? MVHzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE> NVr5NIVJOjN2N{W5OVY>
Hepa1-6 MWPBdI9xfG:|aYOgRZN{[Xl? NWfIWmU3PTEQvF2= NWfi[2hZOmh? NWfVVnhscW6qaXLpeJMh[3W{Y4XtbY4h[W6mIILld5ZmemG2cn;sMYlv\HWlZXSgZZBweHSxc3nz NFToVFMzOzR2Nke1Ny=>
PLC/PRF/5c M2\GVWFxd3C2b4Ppd{BCe3OjeR?= M{\a[VUx|ryP M1zkelFp NFvMfWtxemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=> NH\SZlkzOzR|OEiyOC=>
HCT116 NFv3OIJCeG:ydH;zbZMhSXO|YYm= M1\USFExOM7:TR?= MlHqNU42cA>? NV;qNpdVcW6qaXLpeJMhV3NvaX7keYNm\CClZXzsJIRm[XSq NILDOnUzOzd2NEO1Ny=>
HCEC NHPzfmNHfW6ldHnvckBCe3OjeR?= NW\ETpJkPTEQvF2= M1;DR|czcA>? M4S5VmROW09? MlSwdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=> NVPKZ202OjN5NEKwNVE>
Primary rat cerebral cortical neurons M3vMTWFxd3C2b4Ppd{BCe3OjeR?= M1PIdVExOM7:TR?= NXjvNIplOWh? NHL4dm9xemW4ZX70d{BE\C2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgZ4VtdCCmZXH0bC=> NY\WXmd7OjN5NEGzNVc>
MDA-MB-231  Ml7oRZBweHSxc3nzJGF{e2G7 M4LZT|I2|ryP M4XZVlI1cA>? MX\hZpJw\2G2ZYOgZ5l1d3SxeHnjbZR6KGGwZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMh[W6mIGDBVnAhcW6mdXPl[EBjgSCUZ{O= MmTPNlU{Ozd3NES=
NLRP3-Tet-on-MC/9  MULBdI9xfG:|aYOgRZN{[Xl? M1X6T|ExNTRyzszN MWixNog> MVLheJRmdnWjdHXzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDDRXBUNWG|c3;jbYF1\WRiTlzSVFMhdXW2YX70d{BqdiC2aHWgWIV1NW:wIIP5d5RmdQ>? MlfGNlM4ODN|OEm=
KNS42  M3u5dmFxd3C2b4Ppd{BCe3OjeR?= M3vYSFUx|ryP M1rZN|Fp MlnidoVlfWOnczDj[YxtKGSnYYToJIFv\CClb33wcIV1\Wy7IHHic4xqe2inZDDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBqdiC{ZYPwc45{\SC2bzDBRnQuOjZ|L{LES{9u\XSob4LtbY4h[2:vYnnuZZRqd25? NIHB[IszOzZ7MUG0OS=>
MCF-7  NUC3OVJnSXCxcITvd4l{KEG|c3H5 MXWyNO69VcLi MlzoO|Jp M1S0b4lvcGmkaYTzJIVyfW:uLTDhcoQhPC2RSGStcYVlcWG2ZXSgZZBweHSxc3nz Ml\YNlM3PzV4NEO=
hCMEC/D3  MXLBdI9xfG:|aYOgRZN{[Xl? NFXre3YzPc7:TR?= NUnFeYN7PzKq M1PkT5Jm\HWlZYOgUJR5SSCrbnT1Z4VlKGGyb4D0c5Nqew>? NFzIWVczOzZ4NUG5PC=>
Jurkat MUfBdI9xfG:|aYOgRZN{[Xl? NUPydJVxOTJwNT21NO69VQ>? NXX5Now1OWh? NUPGdVBJ\G:|ZTDk[ZBmdmSnboTsfUB{fXCycnXzd4V{KFOSSD3pcoR2[2WmIGDhdk01KGOuZXH2ZYdmNCCSQWLQJINt\WG4YXflMEBFVkFiZoLh[41mdnSjdHnvckwh[W6mIHzvd5Mhd2ZidnnhZoltcXS7 Ml\aNlM1PDJ7N{[=
CNE-1 M4jBUWFxd3C2b4Ppd{BCe3OjeR?= M1OwO|Ix|ryPwrC= M2fNUFI1cA>? NVqyNHNJcW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NEThOWszOzR{Nki1NC=>
HONE-1 NHPUSlBCeG:ydH;zbZMhSXO|YYm= M1vte|Ix|ryPwrC= NWnEPG1NOjSq NFvrS|lqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo MXSyN|QzPjh3MB?=
astrocytes cell MmTuRZBweHSxc3nzJGF{e2G7 MW[0NO69VQ>? MlmyOog> M2rD[5Jm\HWlZYOg[YFzdHliYYDvdJRwe2m|IHnu[JVk\WRiYomgd5RifXKxc4Dvdolv\Q>? M3L3TFI{PDFzN{e4
U-937 M4XCRWFxd3C2b4Ppd{BCe3OjeR?= NUKwRXpVOTEQvF2= NGrL[5E{OG2rbh?= M2q5[pBz\X[nboTzJHRPTi2rbnT1Z4VlKG6nY4LvdJRwe2m| NGi0ZZczOzRzMEe0PC=>
MDA-MB-231 MXHBdI9xfG:|aYOgRZN{[Xl? M1Lqc|ExOM7:TR?= MoDTNYg> MUPpcohq[mm2czDz[Y5{cXSrenH0bY9vKHSxIGTSRWlNKHWyb36gUXRFUCCmb4fuMZJm\3WuYYTpc44> M32xblI{PDB6NEK5
HeLa  NIXMdGVCeG:ydH;zbZMhSXO|YYm= NVW5fXBDOTByzszN NFm5d3MzcA>? MkK1Zoxw[2u|IFrSV{0yPSCLbnT1Z4V{KEGyb4D0c5Rq[yCFZXzsJGRm[XSq NWrjTopuOjN|NESwOFU>
Ec109 NH24cm5CeG:ydH;zbZMhSXO|YYm= NHnTZokyOM7:TR?= MUG2bC=> MUjicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MoXYNlM{Ozh3Nki=
H460  NGLLb4ZCeG:ydH;zbZMhSXO|YYm= M3\EZ|Ex|ryP NIm4ZXQ3cA>? NYr0NZFM[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? MnflNlM{Ozh3Nki=
HeLa  M3zpNGFxd3C2b4Ppd{BCe3OjeR?= NH63fHM2OM7:TR?= NV7B[JNiOS53aB?= NIDj[Hdi[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>? MV6yN|MxOzhyNB?=
SK-HEP1 MnuxRZBweHSxc3nzJGF{e2G7 NEC5[GYyODEQvF2= MkTlNYg> NWrZ[nNZcW6qaXLpeJMhS3KWMTDhZ5RqfmG2ZXSgZ4F{eGG|ZT2zMEAuPyxiLUisJE06NCCjbnSgdI9tgSiDRGCtdoljd3OnKTDwc4x6dWW{YYPl MWCyN|MxOjZ3MB?=
QGY7701 MWjBdI9xfG:|aYOgRZN{[Xl? NF;ZVIUzPc7:TR?= NGH5WHEyNjWq M4\zWolvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDzeYIuTzFicHjhd4UhcW6mdXPl[EBjgSCGT2igL{ByfWW{Y3X0bY4> Ml6zNlMzPDByNkG=
HepG2 NWm2cmNbSXCxcITvd4l{KEG|c3H5 Mm[3NlDPxE1? NITwSZQ{OG2rbh?= NVHYOZp6cW6qaXLpeJMhfGinIHXubIFv[2WmIHPlcIwh\GWjdHigZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIHHwbYdmdmmwIHHu[EBVWkGLTB?= NGPWNlYzOzJ{NEKzPS=>
U87  M4PpZ2Fxd3C2b4Ppd{BCe3OjeR?= MXSyOe69VQ>? NYC0fG9VOmh? M{TVc4Rm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> M4\zeFI{OjJ7NkK2
HSC-2 NH3lOVJCeG:ydH;zbZMhSXO|YYm= NGf6fmUzPS93MN88US=> MoT0NYg> MonYbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= NEjRSY0zOzF3NUK0PC=>
HSC-4 MUPBdI9xfG:|aYOgRZN{[Xl? M3fDfFI2NzVyzszN NF;BVpcycA>? NF76PXpqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NF7leXQzOzF3NUK0PC=>
CL-1 MX\BdI9xfG:|aYOgRZN{[Xl? MUCyNO69VQ>? NV;QZnFUOWh? MXPicI9kc3NiT2C0OFkhcW6mdXPl[EBk\WyuIHTlZZRp NXrTfFRDOjNzM{G3PFI>
MEL MWTBdI9xfG:|aYOgRZN{[Xl? NInFbnAzOM7:TR?= NWH0elVnOjSq MWHEUXNQ NYHy[I9DcW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= MVSyN|AyPDh6Nx?=
Bel-7402  NVHJUo1YS2G|cHHz[UBC[3SrdnH0bY9vKEG|c3H5 MoXmOVDPxE1? NIPDNFIzcA>? MV3pcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz M1SzeFI{ODB6N{Sy
Eca-109 NGPHTW5CeG:ydH;zbZMhSXO|YYm= MWmyOe69VQ>? NFu1RW4{OG2rbh?= NYrRblBicW6qaXLpeJMhSkpvQkGxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NIK4e5QzOzB5Nkm2Oy=>
MEL Mn3BRZBweHSxc3nzJGF{e2G7 MmH3NlDPxE1? MnTXNYg> NHnze3RFVVOR NHrhUlRqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| MlfqNlMxOTR6OEe=
Bel-7402  NWrYcIpxSXCxcITvd4l{KEG|c3H5 MYC1NO69VQ>? NGLvbJAzcA>? M1HY[olvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> NHHhO3czOzByOEe0Ni=>
L929 M{\MbGZ2dmO2aX;uJGF{e2G7 MoPmNk42|ryP MnrFNYg> M3jNT4lv[3KnYYPld{BTUVBzIHX4dJJme3Orb36gZY5lKGW6YXPldoJifGWmIGTOSu6yNWmwZIXj[YQhdWm2b3Poc45lemmjbDDkfZNnfW6ldHnvckBidmRiUl;TJJBzd2S3Y4Tpc44> M2O2fFI{ODByNUG4
RCC  NEnYbIZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4XOSVExOM7:TR?= MnTRNlRp MVXy[YNwfmW{ZYOgeIhmKH[rYXLpcIl1gSCxZjDj[YxteyCneIDvd4VlKHSxIEG1[E1RT0p{ MV6yNlk6OTR7NB?=
NB2a/d1 NVvWTldmSXCxcITvd4l{KEG|c3H5 MlnBNVAx|ryP NWnxSZJSPzKq MW\heJRmdnWjdHXzJJN1[XW{b4Pwc5JqdmVvaX7keYNm\CClYYPwZZNmKGGldHn2bZR6NCCSQWLQMEBidmRidHH1JINt\WG4YXfl MWqyNlk5QDV2MR?=
T cell NHnXRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPxWmYzPS1zMEFOwG0> MW[yOIg> MY\kc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> MljiNlI6QDJ3M{i=
K562 MYHBdI9xfG:|aYOgRZN{[Xl? MnTwNVAx|ryP NYPmZpNoOWh? MnXaZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? NEGxOYczOjl5MkO3Ni=>
Jurkat  NGLofYVCeG:ydH;zbZMhSXO|YYm= M1zqd|Qx|ryP MXSxbC=> MUnhZo9tcXOqZYOgSoF{VC2rbnT1Z4VlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> MWiyNlk1Ojd|OB?=
BGC-823 MniyRZBweHSxc3nzJGF{e2G7 NHTLSnEyODEQvF2= NX;W[WRuOWh? NGHzPG9x[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= NVXG[Wp2OjJ7Mk[1OFU>
Hep3B Mn7YRZBweHSxc3nzJGF{e2G7 MlzpOVDPxE1? NWXpR5FOOWh? NETTTmJjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= NYTad|JGOjJ7MkOxOVQ>
LLC-PK1 NIfjNIJCeG:ydH;zbZMhSXO|YYm= NYi3SYtTOjEQvF2= NFTM[WIycA>? NV;T[JRyeHKndnXueJMh[2m|cHzheIlvNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gRZRoPSxiYnXjcIlvNTFuIHHu[EBCfGdzMjDwdo91\Wmwcx?= MmXENlI5QTZyM{e=
A549 MXTBdI9xfG:|aYOgRZN{[Xl? NGrwdIQ2OM7:TR?= NInvPW0ycA>? MWHicI9kc3NidHjlJGJCUS2rbnT1Z4VlKGGyb4D0c5Nqe8Li M3i2SlIzQDh5MkG1
SGC-7901  NVXV[VZbSXCxcITvd4l{KEG|c3H5 MlK2NVDPxE1? NF;DfoEzPGh? NIf4ZoVqdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>? NWXJNWp4OjJ6NEi1PVc>
DM6 M{fhVWFxd3C2b4Ppd{BCe3OjeR?= M3PtNlExOM7:TR?= NWfMTpRrPzKq NVzyUoFN[myxY3vzJIJwfGhiRULGMVEh[W6mIFWySpRzNW2nZHnheIVlKGO7dH;0c5hq[2m2eR?= MnuwNlI5OjV|Mki=
MCF-7, MDA-MB-468, Caco-2 NGC3fFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYOVDPxE1? NH[0fIc1QGh? NVTUWnFYcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44hcW6mdXPl[EBjgSC|YYDvcolv M{naRlIzQDByOU[4
A2750  MWLBdI9xfG:|aYOgRZN{[Xl? MUOyNO69VQ>? NULESFBoOmh? MkDiSG1UVw>? MVnicI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MWeyNlc5PDN4Mx?=
U87  M2PEPGFxd3C2b4Ppd{BCe3OjeR?= MVWyNO69VQ>? NE\uPZIzPGh? M1f2Z5Jm\HWlZYOgeIhmKGGyb4D0c5NqeyC{YYTlJIlv\HWlZXSgZpkhWEyDQh?= MnjLNlI4Pzh5OEC=
HT1080 M4LzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTKUnk2OM7:TR?= MYW3[C=> M3T1c4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC= MYOyNlc1ODl6NB?=
A549  NV;GTWg6SXCxcITvd4l{KEG|c3H5 NGfybXU2OM7:TR?= M1\ZU|Jp M37XSZBienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz NVjSdZdwOjJ5MkG4NFQ>
Primary OPC M{X1eWFxd3C2b4Ppd{BCe3OjeR?= NUfJNJFVOc7:TR?= MmnyOogwOjSq NIn3VoZz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO= MVuyNlcxPzN6NR?=
PMNs MVPBdI9xfG:|aYOgRZN{[Xl? NH\mOok1OM7:TR?= MY[2bC=> NV\Xb4JyTE2VTx?= MnnadoV3\XK|ZXSgeIhmKGGvb4XueEBw\iClbHXheoVlKGOjc4Dhd4UuOyC2bzDu[YFzKH[naHnjcIUhdGW4ZXzz M4D3OVIzPjl{NUe3
A549  MmPNRZBweHSxc3nzJGF{e2G7 NUPhcGF1PTEQvF2= NUj4UZk5OWh? NVfFTYRYeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQnHvbJVwe2mmZTDJ MlS1NlI3QDd4M{W=
AGS MV\BdI9xfG:|aYOgRZN{[Xl? NGTyRWMzOM7:TR?= MU[xNog> MYPpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> NXvKUmxMOjJ4OEezPVg>
shC9  NW[3fZBLSXCxcITvd4l{KEG|c3H5 NWXyXolsOTEQvF2= M4HmTFE3cA>? NEfkXpljdHWwdIOgV2hJKGW6cILld5Nqd25iaX6gd4hEQSClZXzsd{BmgHCxc3XkJJRwKGWrdHjldkBRSSCxcjDMVGM> MYeyNlY1OTB7NB?=
primary MEFs NUPtS5FzTnWwY4Tpc44hSXO|YYm= MVGxNog> NHi1OYXDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w M336V|IzPjF|N{[3
3T9 MEFs NX\Xe5dOTnWwY4Tpc44hSXO|YYm= MXKxOog> NVf4[IhKcW6lcnXhd4V{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHHmeIVzKGW2b4Dvd4ll\S22cnXheI1mdnR? Ml3mNlI3OTN5Nke=
3T9 MEFs MVfGeY5kfGmxbjDBd5NigQ>? NWThcYQ{OTiq MkL5eZBz\We3bHH0[ZMhcW6rdHnheI9zKGOjc4Dhd4UuQSCkdYSg[I94dnKnZ4XsZZRmeyCnZn\lZ5RweiClYYPwZZNmeyCjZoTldkBmfG:yb4Pp[IUhfHKnYYTt[Y51 NGXz[XgzOjZzM{e2Oy=>
MDA-MB-231  M3rVPGFxd3C2b4Ppd{BCe3OjeR?= NWP4fIszOjEQvF2= MVy0[C=> NYrIfGV6emWmdXPld{B1cGViY3XscEBieG:ydH;zbZMhcW6mdXPl[EBjgSCvZYTmc5JucW5idILlZZRu\W62IIfhd{B{cWewaX\pZ4FvfGy7 M{\6R|IzPTl|NESx
C6  NX\SU2NVSXCxcITvd4l{KEG|c3H5 M2T3elEx|ryP MmS3NlRp NVjpNmlI[myxY3vzJJRp\SC|dYDwdoV{e2m4ZTDl[oZm[3Rib3[geIhmKHCncITp[IUhd25idnnhZoltcXS7 MU[yNlU5QDl6MB?=
HL-60  M4\oNmFxd3C2b4Ppd{BCe3OjeR?= M1e3XFExOM7:TR?= Ml7TNlRp NVjYXZdPcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> NVe1[5Y1OjJ3NE[2Olk>
HL-60 M1e2WmFxd3C2b4Ppd{BCe3OjeR?= MX6xNE05OM7:TR?= NYf2bIJRPGh? MVfpcohq[mm2czDUS2hSNWmwZIXj[YQh[2WubDDhdI9xfG:|aYRCpC=> NXPwVopUOjJ3MkOyNlk>
BCC MnTwRZBweHSxc3nzJGF{e2G7 MV[1NO69VQ>? MW[xbC=> MWrpcohq[mm2czDERXRUNW2nZHnheIVlKGe{b4f0bEBqdmirYnn0bY9v NGfn[W0zOjVzOUSzOi=>
RAW 264.7 MU\BdI9xfG:|aYOgRZN{[Xl? NX:3[4Y5PTBxMUCw{txO Ml20NYg> NXvCTZVt[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdIOgSG9PNWmwZIXj[YQhelKQQTDjcIVifmGpZR?= NV3LXHB6OjJ2OUG0NlY>
K562 NGrjRZFCeG:ydH;zbZMhSXO|YYm= M3;KWlI2|ryP M1TpOVJp MnnHdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[29vdILlZZRu\W62IIfpeIgh[W23cnXud4lvKEdiYX7kJHRTSUmO M1zFbFIzPDh|N{e3
SGC-7901 NGPRcZRCeG:ydH;zbZMhSXO|YYm= NXHTelJMOjBizszNxsA> M3;IfVJp MWLheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= MoLuNlI1PzF3OEm=
PC3 NWTXbINtSXCxcITvd4l{KEG|c3H5 MlTBNVDPxE1? MlLoOIg> NXrRTpV5[2:3boTldpMh\myjdn;jc5hq\C2rbnT1Z4VlKGOjc4Dhd4UuemWuYYTl[EBieG:ydH;zbZM> NF[xW2EzOjR5MUm3OC=>
SMMC-7721 NUnwPJlySXCxcITvd4l{KEG|c3H5 MmjqOVDPxE1? MWi0PIg> NGXuSoRifHSnboXheIV{KG:WUj3pcoR2[2WmIHHwc5B1d3Orcx?= Mn3vNlI1PjV6M{O=
HeLa  NHf4dWlCeG:ydH;zbZMhSXO|YYm= M1\HW|UxyqEQvF2= M3qxclQwQGh? MXPpcohq[mm2czDTWHMucW6mdXPl[EBt[XSnLYDoZZNmKGGyb4D0c5Rq[yCndnXueJM> MWCyNlQ3ODVyNB?=
HeLa  NVPtVohYSXCxcITvd4l{KEG|c3H5 MnPUOVDDqM7:TR?= NVLFPVNvOWh? MVTzeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>? NUPMTJE1OjJ2NEm0OFA>
T47D  MYDBdI9xfG:|aYOgRZN{[Xl? NFvzZXAyODEQvF2= NWfNN2VKOWh? MWricI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? M3;xTVIzPDBzMU[4
HeLa  NFnkbnZCeG:ydH;zbZMhSXO|YYm= NFi4dIs{OM7:TR?= NXnxfoF4PGh? M2L3bOKhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKh NXX1bW1qOjJ|OUSyOFg>
HCC NV:3NG06SXCxcITvd4l{KEG|c3H5 M2jmelIxKM7:TdMg MW[ybC=> NHzOeVZifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> M3nPfFIzOzR{N{Oy
mESCs Mn34RZBweHSxc3nzJGF{e2G7 M1nKPFIvPc7:TR?= NILsepozcA>? MUfpcohq[mm2czD0bIUhVmGILX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbh?= MlTVNlIzQDV{N{S=
EMT-6  M{fxPGN6fG:2b4jpZ4l1gSCDc4PhfS=> NVLKfmd{OTByzszN NVW3[XJbOWh? MVXwZZJ1cWGubImgZoxw[2unZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhe2m{YX3ld4lv\Q>? MlLHNlIzPTF7MkG=
MCF7 Ml73RZBweHSxc3nzJGF{e2G7 NHXVbWw2OMLizszN M3LBdFFp Mn;0bY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? MW[yNlIzOzN2NR?=
K562 NI[wNlZCeG:ydH;zbZMhSXO|YYm= NH\zNWUzOCEQvF5CpC=> NEDSNFQ1QGh? M2PT[GROW09? M2HGdYJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> M2DjNFIzOjF4MUW4
Molt4-hyg NGmwXWRCeG:ydH;zbZMhSXO|YYm= M2HPUFEx|ryP M17LNlAvPWh? MWTicI9kc3NiZnHycoV{d2xvaX7keYNm\CClYYPwZZNmNTNvbHnr[UBi[3Srdnn0fS=> NXrOU2JlOjZ{N{W4NVE>
HeLa NF7Gbm5CeG:ydH;zbZMhSXO|YYm= NGjzXJQyOM7:TR?= NXXOeJh5OC53aB?= NI\FXXBqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSC2aHWgZ49u[mmwZXSgeJJm[XSvZX70JJdqfGhiZ3;tbZNqdiCQIHHu[EBVWkGLTB?= NEWxdYozOjF5OU[2NS=>
Jurkat T M4DTNWFxd3C2b4Ppd{BCe3OjeR?= NXHlcooxOzEQvF2= NWH2coltOC53aB?= NEO5VoFFVVOR NV7W[3Ns[myxY3vzJJRp\SC8aYLhcU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHXQTmwzOjF3OUi5PC=>
Neutrophil NWHOO2xySXCxcITvd4l{KEG|c3H5 NF22cokzOM7:TR?= NV7lboNPOC53aB?= NEXqXIVifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx MmrFNlYyQTZ6NES=
HCT116 NGj6RnBCeG:ydH;zbZMhSXO|YYm= MnjuOVDDqM7:TR?= NGn1dGkzcA>? MVzy[ZZmenOnczDzfY5memerc4TpZ{BieG:ydH;zbZMh\W[oZXP0d{Bw\iClZXzlZ495cWJiYX7kJG5RSy1zNtMg NHO1Vo0zOjF3OUe1Ni=>
MDA-MB-231  M1fhOGFxd3C2b4Ppd{BCe3OjeR?= MWmyMlUuPy53zszN NI\KXXkzcA>? NWHYSpoxcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigc4YhVUSDLV3CMVI{OSClZXzsd{BqdmS3Y3XkJIJ6KFOGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= NHTocFYzOjFzNUWyOi=>
LNCaP NGW5cplCeG:ydH;zbZMhSXO|YYm= MUm0NO69VQ>? NHXnZ5UzcA>? Mn\4bY5pcWKrdIOgZpV1\WmwIHnu[JVk\WRiY3XscEBieG:ydH;zbZM> Ml60NlIyOTR5NkS=
MB231 Mom3RZBweHSxc3nzJGF{e2G7 NEXaXVcyODEQvF2= Ml\BNYg> Mk\6SG1UVw>? NFfKfoZi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w NHvjZXEzOjFzMkm0NC=>
HCC38  NYi5OpBWSXCxcITvd4l{KEG|c3H5 NYDEUmdXOTByzszN MXuxbC=> M2nqcmROW09? NUPqbVdN[WK{b3fheIV{KHSqZTDpcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCkeTDXSWUyKGmwaHnibZRqd25uIGTSRWlNKHS{ZXH0cYVvfCxiYX7kJJRp\SClb33ibY5ifGmxbh?= MWCyNlEyOjl2MB?=
MDA-MB231 MmraRZBweHSxc3nzJGF{e2G7 NXf1dWhJPTEEoN88US=> MojSNlRp M1nKZWROW09? M2\HeYFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> NHzCT5YzOjFyMUOzOS=>
LNCaP NYPRUGNVSXCxcITvd4l{KEG|c3H5 NV\RcmJrPTEEoN88US=> NX3KVZROOjSq MmHNSG1UVw>? MWjhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo NIjVSpIzOjFyMUOzOS=>
HCT116 MlfNRZBweHSxc3nzJGF{e2G7 NVXGTYhRPTEEoN88US=> NYfzPXk6OjSq MoHISG1UVw>? NIftWYJi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp MXGyNlExOTN|NR?=
Ishikawa  NV7sZY5mSXCxcITvd4l{KEG|c3H5 MnPqNlXPxE1? NWPkOG9OOjSq Mln5doVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? NHX4e|YzOjB6OEmxPC=>
 YD-8  MVnBdI9xfG:|aYOgRZN{[Xl? MV6xNFDPxE1? M1LpS|Fp NH;HZnpqdmirYnn0d{BRVEWRLXnu[JVk\WRiYYDvdJRwe2m| Mmn1NlIxQDZzOEO=
eosinophil  MXzBdI9xfG:|aYOgRZN{[Xl? M1u4fFkx|ryP NIjISoozPGh? NXfYOG85cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA> NGrjTIEzOjB5OUOzOC=>
L929 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknRNk42|ryP NYTMN25uOjSq NIPT[oFqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 MYmyNlAzPzB7Nx?=
YD-8  M4PsUWFxd3C2b4Ppd{BCe3OjeR?= NWThUFVoOTByzszN NEHSXoQycA>? MX3icI9kc3NidHjlJGdUNUiFbD3pcoR2[2WmIHHwc5B1d3Orcx?= NVKwV5luOjJyMkCwO|g>
HBx NWrO[JBqSXCxcITvd4l{KEG|c3H5 NFW2SJIzPc7:TR?= NVjzTZR4PDiq NVLnd|lvTE2VTx?= NYjvb5p7emWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> MV:yNlAzODB5OB?=
U937  NUHVbJh6SXCxcITvd4l{KEG|c3H5 NELudpo2OMLizszN MVmxbC=> M3TxSolvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? Mn\UNlE6QTh5M{G=
HL60 NIPXeXRCeG:ydH;zbZMhSXO|YYm= MofaOFDPxE1? MoH3OFBucW5? NHrMeJBFVVOR MlS1Zoxw[2u|IFLOSGMh[2:vcH;1coR{KGmwZIXj[UBmgHCxc4Xy[UBw\iCyaH;zdIhifGmmeXzz[ZJqdmViYX7kJGRPSSCocnHncYVvfGG2aX;u MYKyNVk5OzJ7Nh?=
M-14 M3LEeGFxd3C2b4Ppd{BCe3OjeR?= MoewNlXPxE1? NGTJbXkxNjWq NY[0eGJVyqCrbnjpZol1eyCkb4ToJJRp\SClcoXk[UBmgHS{YXP0MUBidmRiY3;tdI92dmRvaX7keYNm\CCjcH;weI9{cXN? NF;3flQzOTl3NEm1PS=>
SK-BR-3 Mn7TRZBweHSxc3nzJGF{e2G7 MnPqOVDDqM7:TR?= MYmybC=> M3LpboJtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=> MlvoNlE6ODF|OE[=
MDA-MB-468 M3;VVmFxd3C2b4Ppd{BCe3OjeR?= NUfYVIY2PTEEoN88US=> M1THPFJp NIXoO21jdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> MliyNlE6ODF|OE[=

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products0

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID